Unknown OBSERVATIONAL NCT01630174

IMRT/Pemetrexed/Cisplatin in Esophageal Cancer

Phase I Study of Concurrent Selective Lymph Node Late Course Accelerated Hyper-fractionated Radiotherapy and Pemetrexed, Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma

Sponsor: Shandong Cancer Hospital and Institute

Conditions Esophageal Cancer

Updated 6 times since 2017 Last updated: Jun 27, 2012 Started: Oct 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Esophageal Cancer, this trial is ongoing. The trial is conducted by Shandong Cancer Hospital and Institute and has accumulated 6 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status
Jun 2018 — Jan 2021 [monthly]

Unknown Status
Apr 2018 — Jun 2018 [monthly]

Unknown Status

Phase: NA → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Unknown Status NA

First recorded

Oct 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shandong Cancer Hospital and Institute

Data source: Shandong Cancer Hospital and Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jinan, China